174 related articles for article (PubMed ID: 34008275)
21. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen increase during dutasteride to indicate the need for prostate biopsy: influence of prostatic inflammation.
Sciarra A; Maggi M; Fasulo A; Salciccia S; Gentile V; Cattarino S; Gentilucci A
Urologia; 2017 Aug; 84(3):158-164. PubMed ID: 28430341
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of prostate biopsy in patients under the dutasteride treatment.
Obinata D; Nakahara K; Yoshizawa T; Mochida J; Yamaguchi K; Takahashi S
Medicine (Baltimore); 2022 Nov; 101(44):e31658. PubMed ID: 36343082
[TBL] [Abstract][Full Text] [Related]
24. Decision analysis of dutasteride use for patients with negative prostate biopsy.
Vickers AJ; Sjoberg DD
Urology; 2015 Feb; 85(2):337-41. PubMed ID: 25623680
[TBL] [Abstract][Full Text] [Related]
25. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
[TBL] [Abstract][Full Text] [Related]
26. Dutasteride and prostate cancer.
Kiemeney LA; Bosland MC
N Engl J Med; 2010 Aug; 363(8):793; author reply 794-5. PubMed ID: 20718671
[No Abstract] [Full Text] [Related]
27. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
28. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Kaplan SA
J Urol; 2005 Nov; 174(5):1904-5. PubMed ID: 16217336
[No Abstract] [Full Text] [Related]
29. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.
van Leeuwen PJ; Kölble K; Huland H; Hambrock T; Barentsz J; Schröder FH
Eur Urol; 2011 Feb; 59(2):183-90. PubMed ID: 21130560
[TBL] [Abstract][Full Text] [Related]
31. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
[TBL] [Abstract][Full Text] [Related]
32. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.
Moreira DM; Nickel JC; Gerber L; Muller RL; Andriole GL; Castro-Santamaria R; Freedland SJ
Cancer; 2014 Jan; 120(2):190-6. PubMed ID: 24323568
[TBL] [Abstract][Full Text] [Related]
33. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
34. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
35. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
36. Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment.
Kim TB; Oh JK; Kim KH; Jung H; Yoon SJ; Lee MS; Kim SW
BJU Int; 2012 Dec; 110(11 Pt C):E857-63. PubMed ID: 22755506
[TBL] [Abstract][Full Text] [Related]
37. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
[TBL] [Abstract][Full Text] [Related]
38. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
39. [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].
MMW Fortschr Med; 2003 Feb; 145(9):54. PubMed ID: 12666533
[No Abstract] [Full Text] [Related]
40. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
